海王生物(000078) - 2024 Q3 - 季度财报

Financial Performance - Q3 2024 revenue was CNY 7,921,253,006.34, a decrease of 8.81% year-over-year, and year-to-date revenue was CNY 24,552,692,705.95, down 14.27%[3] - Net profit attributable to shareholders was CNY 807,494.95, up 0.52% year-over-year, while year-to-date net profit was CNY 46,217,326.63, down 47.77%[3] - The net profit after deducting non-recurring gains and losses was CNY -19,166,365.09, a decrease of 67.03% year-over-year, and year-to-date it was CNY 19,735,332.49, down 53.72%[3] - Total operating revenue for the current period is ¥24.55 billion, a decrease of 14.5% from ¥28.64 billion in the previous period[18] - Net profit for the current period is ¥125.85 million, a decline of 32.1% compared to ¥186.01 million in the previous period[19] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 50,668,071.69, a decrease of 71.02% compared to the previous year[3] - The company reported a 71.02% decrease in net cash flow from operating activities, attributed to a decline in sales scale[7] - Cash flow from operating activities generated a net amount of ¥50.67 million, significantly lower than ¥174.85 million in the previous period[21] - The company has seen a decrease in cash flow from investment activities, with a net cash outflow of ¥62.57 million compared to a larger outflow of ¥283.78 million in the previous period[21] - The net increase in cash and cash equivalents was CNY -337,966,071.03, compared to CNY -239,957,901.02 in the same period last year[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 31,318,856,006.77, a decrease of 3.05% from the end of the previous year[3] - Current assets totaled CNY 27.85 billion, down from CNY 28.81 billion, indicating a decrease of about 3.3%[15] - Total liabilities decreased from CNY 28.09 billion to CNY 27.13 billion, a reduction of about 3.4%[16] - The total assets decreased from CNY 32.30 billion at the beginning of the period to CNY 31.32 billion at the end, representing a decline of approximately 3%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 131,564[8] - The largest shareholder, Shenzhen Haiwang Group, holds 46.23% of the shares, totaling 1,216,445,128 shares[8] - The company announced a significant share transfer agreement on July 28, 2024, where Haiwang Group transferred 315,734,800 shares, representing 12% of the total shares, to Silk Group[11] - Following the share transfer, Haiwang Group and its concerted actors will have zero voting rights associated with 900,710,328 shares[11] Investment and Expenditures - Investment income decreased by 118.22% year-over-year due to increased losses from the disposal of subsidiaries[7] - Development expenditures rose to CNY 102.09 million from CNY 90.98 million, an increase of approximately 12.3%[16] - The company plans to expand its logistics warehouse projects, which contributed to a 50.98% increase in construction in progress[6] Accounting and Reporting - The report for the third quarter was not audited, indicating that the figures may be subject to change upon final review[22] - The company has adopted new accounting standards starting from 2024, which may affect future financial reporting[22]